Diagnosis of Periodontal Disease Using Genetic Marker in Saliva

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study is to identify the novel periodontal disease biomarkers using differentially expressed microRNA in the saliva. The severity of chronic periodontal diseases and the time of pre- and post-treatment are major classification criteria. The obtained data will secure the foundation for the development of a new non-invasive diagnostic methods for early diagnosis & prognosis prediction of periodontal disease.

Official Title
-----------------
Identification of Novel Periodontal Disease Biomarkers Using microRNA Expression in Saliva

Conditions
-----------------
Chronic Periodontitis

Intervention / Treatment
-----------------
* Procedure: non-surgical periodontal therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A. Severe Periodontal Disease Patients with chronic severe periodontitis Primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients. subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing A. Moderate Periodontal Disease Patients with chronic moderate periodontitis Primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients. subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing C. Healthy Control Healthy periodontal patients ( more than 20 permanent teeth are present , in all parts of deep periodontal pockets measuring 4mm or less, and height is 2mm or less clinical attachment person) subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing Exclusion Criteria: Received periodontal treatment within the last six months recently taken antibiotics within 3 months if you need a prescription antibiotic prophylaxis taking the drug can affect periodontal status for a long period of time pregnant or breastfeeding In case of oral inflammatory mucosal disease (Lichen planus, etc.) A history of alcoholism or drug abuse if other special systemic disease (high blood pressure) ages under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: severe periodontitis group<br>non-surgical periodontal therapy | Procedure: non-surgical periodontal therapy<br> <br> |
| Experimental: Moderate periodontitis group<br>non-surgical periodontal therapy | Procedure: non-surgical periodontal therapy<br> <br> |
| No Intervention: healthy control<br>No treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression level of MicroRNAs using Microarray |  | Change from Baseline in expression level of MicroRNAs at 1,6,12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression level of cytokines using multiple cytokine analysis | Pro-inflammatory biomarker : interleukin(IL)-1a, IL-1b, IL-6, IL-8 Matrix metalloproteinase(MMP) : MMP-8, MMP-9 Anti-inflammatory biomarker: IL-10, inhibitor of MMP (TIMP)-1 | Change from Baseline in expression level of cytokines at 1,6,12 months |